NuVasive Announces First Patient in Japan Treated with XLIF(R) Technique
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is proud to announce that the very first eXtreme Lateral Interbody Fusion (XLIF(R)) procedures were performed yesterday and today at two different hospitals in Japan. NuVasive has received regulatory Shonin approval for several products to offer the XLIF surgical technique as a minimally invasive option for lumbar spine fusion to patients and surgeons in Japan. The approval furthers the Company's ability to participate in the Japanese market, adding the XLIF approach to the cervical and posterior products that were approved for use late last year.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.